Hong Kong (CNN)Chinese scientists will become the first in the world to inject people with cells modified using gene-editing technology in a groundbreaking clinical trial next month.
A team led by Lu You, an oncologist at Sichuan University's West China Hospital in Chengdu, received ethical approval from the hospital's review board on July 6 to test gene-edited cells on lung cancer patients next month, according to scientific journal Nature.
The cells will be modified using CRISPR-Cas9 -- a new method of genetic engineering that allows scientists to edit DNA with precision and relative ease.
Hong Kong (CNN)Chinese scientists will become the first in the world to inject people with cells modified using gene-editing technology in a groundbreaking clinical trial next month.
Please Wait...
"This technique is of great promise in bringing benefits to patients, especially the cancer patients whom we treat every day," Lu told the journal.
CRISPR stands for clustered, regularly interspaced, short palindromic repeats -- regular patterns of DNA sequences which can be edited out of genes.
Cas9 is a type of modified protein injected into a body to work on the DNA, like a pair of scissors that can snip the genes.
The technique is based on a decade-old discovery that certain bacterial cells can identify invading viruses and chop up their DNA. CRISPR-Cas9 adapts that technique to allow us to edit genes, removing harmful diseases and even allowing the creation of hybrid human-animal organs to fill the transplant gap.
CRISPR stands for clustered, regularly interspaced, short palindromic repeats -- regular patterns of DNA sequences which can be edited out of genes.
Cas9 is a type of modified protein injected into a body to work on the DNA, like a pair of scissors that can snip the genes.
The technique is based on a decade-old discovery that certain bacterial cells can identify invading viruses and chop up their DNA. CRISPR-Cas9 adapts that technique to allow us to edit genes, removing harmful diseases and even allowing the creation of hybrid human-animal organs to fill the transplant gap.
